Microvascular Therapeutics
Tucson
About Microvascular Therapeutics
Microvascular Therapeutics develops MVT-100, a new, patented ultrasound contrast agent. It may serve as a platform for developing agents for molecular imaging and image-guided therapy due to its neutral surface chemistry. Microvascular Therapeutics-100 has a neutral surface chemistry and could be used to develop agents for molecular imaging and image-guided therapy. The company has created an accelerated development path that could lead to MVT-100 approval for echocardiography.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $5.6M
- Last round: Grant (Oct 2023)
- Website: mvtpharma.com
Industries & Categories
Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/microvascular-therapeutics-80915 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.